Prognostic and predictive value of plasma D-dimer levels in patients with small-cell lung cancer

Int J Clin Oncol. 2018 Dec;23(6):1070-1075. doi: 10.1007/s10147-018-1320-5. Epub 2018 Aug 27.

Abstract

Background: To investigate the predictive value of plasma D-dimer levels for short-term therapeutic effect and progression-free survival (PFS) in patients with small-cell lung cancer (SCLC); and to analyze the correlation between baseline plasma D-dimer levels and other clinicopathological features. The aim of the study was to investigate whether the levels of plasma D-dimer could serve as a predictive and prognostic factor in patients with SCLC.

Methods: A retrospective review of the clinicopathological data of 160 patients with pathologically confirmed SCLC, who were treated at the Department of Thoracic Oncology of Tianjin Medical University Tumor Institute and Hospital between June 2011 and June 2016, was performed. At the same time, we collected 100 patients with benign pulmonary diseases as a control group. The correlations between baseline plasma D-dimer levels and other clinical features, therapeutic effect and PFS were analyzed statistically.

Results: The level of plasma D-dimer in patients with SCLC was significantly higher than that of patients with benign pulmonary diseases (P = 0.001). The PFS of patients with elevated D-dimer levels before therapy were significantly shorter than that of patients with normal D-dimer levels (6.0 versus 7.5 months, P = 0.013). The patients whose plasma D-dimer level always (before and after treatment) in the normal range have the best prognosis, and continuously elevated D-dimer carried out a poor prognosis (8.0 versus 5.0 months). According to multivariate analysis, elevated D-dimer level was confirmed to be an independent prognostic factor for worse survival (P = 0.029). The level of D-dimer was associated with tumor stage, the level of neuron-specific enolase, the presence of distant metastasis, hyponatremia, and the Karnofsky performance status score; and levels decreased when therapy was effective, but increased when the disease progressed.

Conclusions: High levels of baseline plasma D-dimer may indicate advanced disease stage and poor prognosis. Therefore, plasma D-dimer levels could serve as a predictive and prognostic factor in patients with SCLC.

Keywords: D-dimer; Progression-free survival; Small-cell lung cancer; Therapeutic effect.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / blood*
  • Case-Control Studies
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis*
  • Humans
  • Lung Neoplasms / blood*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Pneumonia / blood*
  • Pneumonia / drug therapy
  • Pneumonia / pathology
  • Prognosis
  • Retrospective Studies
  • Small Cell Lung Carcinoma / blood*
  • Small Cell Lung Carcinoma / drug therapy
  • Small Cell Lung Carcinoma / pathology
  • Survival Rate
  • Tuberculoma / blood*
  • Tuberculoma / drug therapy
  • Tuberculoma / pathology
  • Young Adult

Substances

  • Biomarkers, Tumor
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D